Skip to content

Yoga for lung functions in COVID-19 survivors

Effect of Yoga-based Rehabilitation on pulmonary function in COVID-19 survivors with respiratory sequelae: A PROBE trial - Re-Cover

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/036829
Enrollment
104
Registered
2021-09-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Yoga Based Rehabilitation including loosening exercises, breathing exercises, asanas, pranayama and guided relaxation: First 3 sessions will be contact session with in the first week of

Sponsors

All India Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a)Known case of COVID patients with respiratory symptoms on screening (RT-PCR negative or 4 weeks to 8 weeks from the onset of first symptom) b)Patients with forced vital capacity(FVC) c)Patients of both sex and age of18-75years d)Patients who are able and willing to practice any form of exercise when recruited under the study e)Patients who are not engaged in regular and structured yoga practice.

Exclusion criteria

Exclusion criteria: a)Patients with forced vital capacity FVC b)Previous pulmonary complications like severe asthma, COPD, bronchiectasis, interstitial lung disease(IL) c)Known cases of CAD with moderate to severe LV dysfunction, patients with a history of CV or neurodegenerative diseases. d)Lactating and pregnant women. e)Patients currently participating in any other clinical trials with intervention.

Design outcomes

Primary

MeasureTime frame
Pulmonary Function: Diffusion lung capacity for carbon monoxide (DLCO), Forced Vital capacity (FVC), Forced expiratory volume in first second (FEV1), Total lung capacity (TLC) using Pulmonary function testTimepoint: Baseline, after 6 weeks and at the end of 12 weeks

Secondary

MeasureTime frame
Severity of dyspnea using UCSD Shortness of Breath Questionnaire. Exercise capacity using 6-minute walk test Inflammatory markers such as Interleukin-6(IL-6) and C-reactive protein (CRP). Total severity score, presence of significant extension of fibrotic abnormalities, ground glass Opacities (GGO) and consolidation, lobar distribution and linear opacities using HRCT of lungs Psychological assessment using general Anxiety Disorder-7(GAD-7), Patient Health Questionaire9 (PHQ-9) Health related quality of life (QOL) using short form (SF-36)Timepoint: Baseline, after 6 weeks and at the end of 12 weeks

Countries

India

Contacts

Public ContactRandeep Guleria

AIIMS, New Delhi

randeepguleria2002@yahoo.com9810184738

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026